Adocia aims to deliver innovations through 3 main axis:

• Biobetters: products offering high medical and usability benefits, based on already approved therapeutic proteins
• Multi-hormonal combinations: by combining hormones with complementary or synergistic effects, Adocia reveals new medical benefits for people suffering from metabolic diseases
• Cell Therapy: in order to improve cell therapy techniques and make them available to the greatest number of people, Adocia is developing a hydrogel matrix capable of ensuring the viability and functionality of implanted cells. This long-term solution offers to patients the freedom to suspend their chronic medications, and do not require the use of life-long immunosuppressant treatment.

Funding : Public company (IPO at Euronext in 2012)